BMJ 1994;309:299-304 (30 July)

Papers

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

A Leizorovicz, G Simonneau, H Decousus, J P Boissel 

Service de Pharmacologie Clinique, BP 3041, 69394 Lyons Cedex 03, France Service de Pneumologie, Hopital A, Beclere, 92140 Clamart, France Hopital Bellevue, 42023 St Etienne Cedex, France Correspondence to: Dr Leizorovicz.

Abstract

Objective : To compare the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis for the reduction of recurrent thromboembolic events, death, extension of thrombus, and haemorrhages.
Design : Meta-analysis of results from 16 randomised controlled clinical studies.
Subjects : 2045 patients with established deep20venous thrombosis.
Intervention : Treatment with low molecular weight heparins or unfractionated heparin.
Main outcome measures : Incidences of thromboembolic events (deep venous thrombosis or pulmonary embolism, or both); major haemorrhages; total mortality; and extension of thrombus.
Results : A significant reduction in the incidence20of thrombus extension (common odds ratio 0.51, 95% confidence interval 0.32 to 0.83; P=0.006) in favour of low molecular weight heparin was observed. Non-significant trends also in favour of the low molecular weight heparins were observed for the recurrence of thromboembolic events (0.66, 0.41 to 1.07; P=0.09), major haemorrhages (0.65, 0.36 to 1.16; P=0.15), and total mortality (0.72, 0.46 to 1.4; P=0.16).
Conclusions : Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in the treatment of venous thrombosis. These results, however, remain to be confirmed by using clinical outcomes in suitably powered clinical trials.

Clinical implications

  • Clinical implications

  • Unfractionated heparin as a first line treatment followed by an oral anticoagulant is the accepted therapeutic approach for deep venous thrombosis

  • Despite treatment, 5-10% of patients suffer from recurrent thromboembolic events in the months after the initial deep venous thrombosis

  • More than 2000 patients have been enrolled in 16 controlled clinical trials comparing the efficacy and safety of low molecular weight heparins and unfractionated heparin; none of these trials allows definitive conclusions to be drawn

  • The results from this meta-analysis show a global significant trend in favour of low molecular weight heparins for a venographic outcome (thrombus extension); although there were favourable trends for clinical outcomes (recurrent thromboembolic events, mortality) and apparently better safety (major haemorrhage), these did not reach significance

  • Although some clinicians may even now prefer to use low molecular weight heparins because they are easier to administer and do not require adjustment of the dose by laboratory analysis, their clinical superiority needs to be confirmed in larger scale clinical trials


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Possible benefits of low molecular weight heparins
L Breimer
BMJ 1994 309: 1019. [Extract] [Full Text]

This article has been cited by other articles:

  • Syed, F.F., Beeching, N.J. (2005). Lower-limb deep-vein thrombosis in a general hospital: risk factors, outcomes and the contribution of intravenous drug use. QJM 98: 139-145 [Abstract] [Full text]  
  • Quinlan, D. J., McQuillan, A., Eikelboom, J. W. (2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED 140: 175-183 [Abstract] [Full text]  
  • The Superficial Thrombophlebitis Treated by Enoxap, (2003). A Pilot Randomized Double-blind Comparison of a Low-Molecular-Weight Heparin, a Nonsteroidal Anti-inflammatory Agent, and Placebo in the Treatment of Superficial Vein Thrombosis. Arch Intern Med 163: 1657-1663 [Abstract] [Full text]  
  • Hamel, E., Pacouret, G., Vincentelli, D., Forissier, J. F., Peycher, P., Pottier, J. M., Charbonnier, B. (2001). Thrombolysis or Heparin Therapy in Massive Pulmonary Embolism With Right Ventricular Dilation : Results From a 128-Patient Monocenter Registry. Chest 120: 120-125 [Abstract] [Full text]  
  • Breddin, H. K., Hach-Wunderle, V., Nakov, R., Kakkar, V. V., The CORTES Investigators, (2001). Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis. NEJM 344: 626-631 [Abstract] [Full text]  
  • Kalafut, M. A., Gandhi, R., Kidwell, C. S., Saver, J. L. (2000). Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia. Stroke 31: 2563-2568 [Abstract] [Full text]  
  • Dolovich, L. R., Ginsberg, J. S., Douketis, J. D., Holbrook, A. M., Cheah, G. (2000). A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous Thromboembolism: Examining Some Unanswered Questions Regarding Location of Treatment, Product Type, and Dosing Frequency. Arch Intern Med 160: 181-188 [Abstract] [Full text]  
  • The Frax.I.S. Study Group, (1999). Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 20: 1553-1562 [Abstract]  
  • Zed, P. J., Tisdale, J. E., Borzak, S. (1999). Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes. Arch Intern Med 159: 1849-1857 [Abstract] [Full text]  
  • Gould, M. K., Dembitzer, A. D., Doyle, R. L., Hastie, T. J., Garber, A. M. (1999). Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED 130: 800-809 [Abstract] [Full text]  
  • McCollum, C. (1998). Avoiding the consequences of deep vein thrombosis. BMJ 317: 696-697 [Full text]  
  • Leadley, R. J. Jr, Kasiewski, C. J., Bostwick, J. S., Bentley, R., Dunwiddie, C. T., Perrone, M. H. (1998). Inhibition of Repetitive Thrombus Formation in the Stenosed Canine Coronary Artery by Enoxaparin, But Not by Unfractionated Heparin. Arterioscler. Thromb. Vasc. Bio. 18: 908-914 [Abstract] [Full text]  
  • Bounameaux, H. (1998). Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism. Vasc Med 3: 41-46 [Abstract]  
  • Johnson, M. (1997). How do palliative physicians manage venous thromboembolism?. Palliat Med 11: 462-468 [Abstract]  
  • The Columbus Investigators, (1997). Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. NEJM 337: 657-662 [Abstract] [Full text]  
  • Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Azarian, R., Laurent, M., Hirsch, J.-L., Ferrari, E., Bosson, J.-L., Mottier, D., Beau, B., The Thesee Study Group, (1997). A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism. NEJM 337: 663-669 [Abstract] [Full text]  
  • Weitz, J. I. (1997). Low-Molecular-Weight Heparins. NEJM 337: 688-699 [Full text]  
  • Johnson, M. (1997). Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 11: 306-312 [Abstract]  
  • Pacouret, G., Alison, D., Pottier, J.-M., Bertrand, P., Charbonnier, B. (1997). Free-Floating Thrombus and Embolic Risk in Patients With Angiographically Confirmed Proximal Deep Venous Thrombosis: A Prospective Study. Arch Intern Med 157: 305-308 [Abstract]  
  • Girolami, A. (1997). Home Treatment Versus Early Discharge From the Hospital: A Dilemma in the Management of Proximal Vein Thrombosis With Low Molecular Weight Heparins. CLIN APPL THROMB HEMOST 3: 66-68  
  • Ginsberg, J. S. (1996). Management of Venous Thromboembolism. NEJM 335: 1816-1829 [Full text]  
  • Schafer, A. I. (1996). Low-Molecular-Weight Heparin -- An Opportunity for Home Treatment of Venous Thrombosis. NEJM 334: 724-726 [Full text]  
  • Greenfield, L. J., Proctor, M. C. (1996). Diagnosis and Management of Pulmonary Embolism. Ann. Thorac. Surg. 61: 1037-1037 [Full text]  
  • Kay, R., Wong, K. S., Yu, Y. L., Chan, Y. W., Tsoi, T. H., Ahuja, A. T., chan, F. L., Fong, K. Y., Law, C. B., Wong, A., Woo, J. (1995). Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke. NEJM 333: 1588-1594 [Abstract] [Full text]  
  • Amiral, J. (1995). State-of-the-Art Review: Usefulness of Laboratory Techniques for Evaluating Antithrombotic Efficacy of New Therapeutic Strategies. CLIN APPL THROMB HEMOST 1: 243-259 [Abstract]  
  • Lensing, A. W. A., Prins, M. H., Davidson, B. L., Hirsh, J. (1995). Treatment of Deep Venous Thrombosis With Low-Molecular-Weight Heparins: A Meta-analysis. Arch Intern Med 155: 601-607 [Abstract]  
  • Breimer, L (1994). Possible benefits of low molecular weight heparins. BMJ 309: 1019-1019 [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ